ID: ALA5290452

Max Phase: Preclinical

Molecular Formula: C62H78IN5O2

Molecular Weight: 925.34

Associated Items:

Representations

Canonical SMILES:  C[N+]1=C(/C=C/C=C/C=C2\N(CCCCCC(=O)NCCCCCCn3cc(CCCCN4CCC5(CC4)OCc4ccccc45)c4ccccc43)c3ccccc3C2(C)C)C(C)(C)c2ccccc21.[I-]

Standard InChI:  InChI=1S/C62H77N5O2.HI/c1-60(2)52-30-16-19-33-55(52)64(5)57(60)35-10-8-11-36-58-61(3,4)53-31-17-20-34-56(53)67(58)43-24-9-12-37-59(68)63-40-22-6-7-23-42-66-46-48(50-28-14-18-32-54(50)66)26-21-25-41-65-44-38-62(39-45-65)51-29-15-13-27-49(51)47-69-62;/h8,10-11,13-20,27-36,46H,6-7,9,12,21-26,37-45,47H2,1-5H3;1H

Standard InChI Key:  PYGSKQVDDNNOJX-UHFFFAOYSA-N

Associated Targets(Human)

SIGMAR1 Tclin Sigma opioid receptor (6358 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TMEM97 Tchem Sigma intracellular receptor 2 (973 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

SIGMAR1 Sigma-1 receptor (3326 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Tmem97 Sigma intracellular receptor 2 (922 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 925.34Molecular Weight (Monoisotopic): 924.6150AlogP: 13.22#Rotatable Bonds: 21
Polar Surface Area: 52.75Molecular Species: BASEHBA: 5HBD: 1
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 9.58CX LogP: 9.94CX LogD: 7.78
Aromatic Rings: 5Heavy Atoms: 69QED Weighted: 0.05Np Likeness Score: -0.33

References

1. Abatematteo FS, Majellaro M, Montsch B, Prieto-Díaz R, Niso M, Contino M, Stefanachi A, Riganti C, Mangiatordi GF, Delre P, Heffeter P, Sotelo E, Abate C..  (2023)  Development of Fluorescent 4-[4-(3H-Spiro[isobenzofuran-1,4'-piperidin]-1'-yl)butyl]indolyl Derivatives as High-Affinity Probes to Enable the Study of σ Receptors via Fluorescence-Based Techniques.,  66  (6): [PMID:36919956] [10.1021/acs.jmedchem.2c01227]

Source